Navigation Links
Health Robotics Releases Results of First 20 i.v.STATION's Return On Investment (ROI) Studies in the USA and Canada
Date:9/8/2010

Health Robotics Releases Results of First 20 i.v.STATION's Return On Investment... -- BOZEN, SUD-TIROL, Italy, September 8, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Health Robotics Releases Results of First 20 i.v.STATION's Return On Investment (ROI) Studies in the USA and Canada

 

BOZEN, SUD-TIROL, Italy, September 8, 2010 /PRNewswire/ -- Health Robotics released the results of the first 20 financial i.v.STATION studies conducted by selected North American channel partners at various Academic, Community, Pediatric, and Oncology hospitals in Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Ohio, Ontario, Pennsylvania, Quebec, and Texas. These studies compared the direct costs of i.v.STATION-produced sterile doses to compounded IVs manufactured by 6 Pharmacy Outsourcing and Pre-Mix/Frozen solutions companies. Health Robotics' web-registered authorized users may access i.v.STATION's ROI case studies and custom Microsoft Excel tools at http://www.health-robotics.com/en/solutions/i-v-station/

"i.v.STATION's $300,000 price, combined with its plug-and-play installation, flexibility of IV Bags/Vials/Syringes, ISO-5 controlled environment, and unprecedented robotic throughput, has already revolutionized Non-Hazardous Sterile Compounding in North America. Multiple hospital studies have proven an i.v.STATION's 3-to-1 cost advantage over Pre-Mix/Frozen solutions by Baxter, B. Braun, and Hospira, resulting on an average 8-month payback period to American hospitals utilizing between 1,200 and 1,400 median Minibag Plus, Duplex, or ADD-Vantage IV doses per month. As many North American hospitals have lately been forced towards increased IV Outsourcing as a result of recent IV drug shortages, i.v.STATION arrives at the right place and at the right time, offering a much more cost effective solution to the widespread scarcity problem in selected antibiotics, pain therapy, and other IV drug classes, while providing Health-System Pharmacies with much more control over Batch IV production and reduced IV waste," stated Gaspar DeViedma, Health Robotics' Executive Vice President.

i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost effective, and ready-to-administer intravenous patient doses. i.v.STATION offers unprecedented reduction of IV medication errors, USP 797 compliance, compatibility with 75+ different Syringe and IV Bags brands/sizes, reduction of IV waste, and significant labor savings: all within a scalable, cost-effective, distributed, and fail-safe architecture.

"i.v.STATION has also consistently revealed a 6-to-1 cost advantage over outsourced custom IV manufacturing offered by Ameridose, CAPS, and PharMEDium in multiple North American local markets, yielding an average 6-month payback period to North American Health-System Pharmacies that typically custom-outsource between 600 and 800 IV doses per month, and a 12-month payback period for those hospitals outsourcing approximately 350 IV doses per month. These outstanding results amply justify Health Robotics' prior announcement that it had ended its 2010 i.v.STATION early-adopter discount program in North America this Summer. It is extremely rare these days to find technologies with hard-dollar cost-justification cycles of less than 12 months. We look forward to continue these studies over the next three months at North American Health-Systems that exclusively compound sterile IV doses in-house without custom-IV-outsourcing or Pre-Mix solutions.", concluded Mr. DeViedma.

About Health Robotics:

Health Robotics is the undisputed global leading supplier of life-critical intra-venous medication robots, providing over 160 hospital installations in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs], i.v.SOFT(TM) [manual compounding software], MEDarchiver(TM) [life-critical clinical information system], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

For additional information, please contact: Claudia Flaim, Marketing Coordinator Altmanstrasse 9/A, Bozen, I-39100 flaim@health-robotics.com Phone: +39-0471-200-372
'/>"/>

SOURCE Health Robotics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
3. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
4. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
5. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
6. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
7. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
8. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
9. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):